Sun Pharma licenses global rights to LIB Therapeutics' cholesterol drug lerodalcibep
The agreement gives Sun Pharma rights to the once-monthly PCSK9 inhibitor lerodalcibep across global markets excluding the US and China.
Sun Pharma has secured exclusive licensing, commercialisation and manufacturing rights to LIB Therapeutics' lerodalcibep worldwide outside the US and China.
The deal adds an EU-approved once-monthly PCSK9 inhibitor, marketed as Lyrokaul in Europe, to Sun Pharma's portfolio in exchange for undisclosed upfront and milestone payments plus royalties.
Field | Content |
Field | Content |
Alert Type | Licensing Agreement |
Companies | Sun Pharma; LIB Therapeutics |
Deal Type | Exclusive licensing, commercialisation and manufacturing agreement |
Asset | Lerodalcibep |
Brand | Lyrokaul in the European Union |
Therapy Area | Cardiovascular disease / lipid management |
Target | PCSK9 |
Technology/Modality | Once-monthly injectable PCSK9 inhibitor |
Geography | Worldwide excluding the US and China |
Deal Value | Financial amounts not disclosed |
Deal Economics | Upfront payment, milestone payments and royalties |
What Happened | Sun Pharma secured exclusive rights to lerodalcibep in markets worldwide excluding the US and China. |
Why It Matters | The transaction gives Sun Pharma access to a differentiated once-monthly cholesterol-lowering therapy with an existing European regulatory approval. |
Strategic Rationale | The agreement expands Sun Pharma's cardiovascular portfolio and provides a platform for commercialising lerodalcibep across multiple international markets. |
Potential Impact | The partnership could broaden global access to lerodalcibep while strengthening Sun Pharma's position in lipid management. |
Key Takeaway | Sun Pharma gains broad international rights to LIB Therapeutics' once-monthly PCSK9 inhibitor. |
What to Watch | Market launches, reimbursement decisions and commercial uptake outside the US and China. |
Primary Source | Sun Pharma |
Relevant Date | 28 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti